| De Novo Myelodysplastic Syndrome studied in …STUDIED_INderived10 of 21show all (up to 200) |
|---|
| → studied in | NCT00801489Phase 2 · recruiting Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00843882Phase 3 · active not recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02115295Phase 2 · recruiting Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00357565Phase 2 · completed Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00588991Phase 1 · completed Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01812252Phase 2 · completed Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01904136Phase 1/Phase 2 · completed Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02728050Phase 1/Phase 2 · completed Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02553941Phase 1 · completed Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01168219Phase 2 · completed Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia · condition mapped ONTOLOGY_EXACT · 21 trials mapped (3 active) | — | — | De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |